The in vitro study of TNF promoter polymorphism (SNP) function was stimulated by the numerous case-control (association) studies of the polymorphisms in relation to human disease and the appearance of several studies claiming to show a functional role for these SNPs provided a further impetus to researchers interested in the role of TNF in their disease of interest. In this review we consider case-control studies, concentrating on the autoimmune and inflammatory diseases rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis, and asthma, and on infectious diseases including malaria, hepatitis B and C infection, leprosy and sepsis/septic shock. We also review the available evidence on the functional role of the various TNF promoter polymorphisms. In general, case-control studies have produced mixed results, with little consensus in most cases on whether any TNF polymorphisms are actually associated with disease, although results have been more consistent in the case of infectious diseases, particularly malaria. Functional studies have also produced mixed results but recent work suggests that the much studied À308G/A polymorphism is not functional, while the function of other TNF polymorphisms remains controversial. Studies of the TNF region are increasingly using extended haplotypes that can better capture the variation of the MHC region.
Introduction
The prominent role played by tumor necrosis factor (TNF) in inflammation and its relevance to both infectious and autoimmune diseases 1 has led to great interest in both the regulation of the TNF gene, and the possibility that variants of the gene or deregulation of its production may be associated with pathology. That TNF is involved in pathology has been convincingly demonstrated by many in vitro and animal studies. TNF was implicated in the pathogenesis of a localized autoimmune disease with the demonstration that transgenic mice expressing human TNF coupled to the 3 0 untranslated region of b globin developed a striking polyarthritis. 2 TNF knockout mice showed that TNF is essential in resistance to infectious disease. 3 That these findings were relevant to human autoimmune/inflammatory diseases is evidenced by the high efficacy of anti-TNF antibodies (Infliximab) and recombinant soluble chimeric receptor in treating rheumatoid arthritis (RA) and Crohn's disease. 4, 5 More recently, their significance was further highlighted in human infectious disease, when the observation was made that in patients treated with Infliximab, reactivation and a severe course of tuberculosis is strongly over-represented 6 These latter findings indicate an important role for TNF in controlling M. tuberculosis and most probably other intracellular infections in humans.
The level of TNF production in healthy individuals shows wide and stable variation, with high and low producer phenotypes present in the population, 7, 8 indicating a substantial genetic contribution to TNF regulation. In an important paper, Westendorp et al 9 showed that the levels of both TNF and IL-10 in firstdegree relatives of patients with meningococcal disease strongly determined the likelihood of patient survival. They also showed a strong concordance of TNF levels in monozygotic twins. This study demonstrated that the influence of genetic variation on the regulation of TNF could have a major impact on the outcome of disease. The source of this genetic variation is unknown and the extensive search to identify mutations in the coding regions of TNF has not disclosed such variation. Therefore, attention has focused on the TNF promoter, encouraged by the identification of a number of singlenucleotide polymorphisms (SNPs). Eight DNA variants or 'SNPs' have been described within the TNF promoter, at positions À1031T/C, À863C/A, À857C/T, À575G/A, À376G/A, À308G/A, À244G/A, and À238G/A [10] [11] [12] [13] [14] [15] [16] relative to the transcription start site (Figure 1 ). The interest in these genetic variants derives from the possibility that the genetic changes they introduce, in comparison to the common form, could affect the binding of transcription factors, controlling the activity of the promoter and resulting mRNA and protein levels.
The regulation of TNF is extensive and begins with the signals that initiate its production. The major source of TNF production is the monocyte/macrophage cell population, but many other cell types, including T lymphocytes and epithelial cells, also produce TNF in response to a range of stimuli. 17, 18 The binding of transcription factors, often cell specific, results in the transcription of the gene. Control at this point is important to the overall levels of TNF availability, but subsequent steps also play a significant role. The 3 0 UTR of the TNF gene contains a rapid decay motif 19 common to other cytokine genes, known as the AU-rich element (ARE), and results in rapid clearance of the mRNA transcript. Stabilization of transcripts is a major regulatory step. Once the protein has been translated to its precursor form it is inserted in the cell membrane as a pro-TNF 26 kDa form. Membrane-bound TNF may play some role in cell-cell interactions 20 but full activation requires proteases, including TACE and several MMPs, 21 to cleave the protein. Once released as a bioactive trimer it exerts its function by interaction with its membrane receptors TNFRSF1A (TNFRI) and TNFRSF1B (TNFRII). TNF bioactivity is further regulated by membrane-shedded TNF receptors, that can both antagonize TNF, serving a buffer function, or stabilize the bioactive form. 22 At all stages of this regulation, extensive networks of gene products are involved in the production, modulation and decay of TNF. Any one of these genes is a potential candidate for the genetic factor(s) controlling both individual levels of TNF and the explaining the (postulated) role of TNF in many diseases.
Nevertheless, the broad role of TNF has inspired investigators with an interest in a wide range of diseases to consider TNF itself as a potential candidate gene and a large number of case-control studies have appeared that have analysed TNF promoter SNPs or TNF locus microsatellites. The association or case-control study is a simple and convenient method to analyse the genetic contribution to disease when a defined patient group is available along with a well-matched group of healthy individuals with the same ethnic background. The frequency of the genetic factor under investigation is compared between these two groups and any factor that is more or less frequent in the patient group is a possible candidate element predisposing to or protecting against disease. Any association that is found may be attributed to the SNP/marker itself, if there is sufficiently compelling data showing that the variant affects regulatory or protein functions, but in most cases the association is recognized as an indication that there is some genetic factor linked to the marker that is modifying risk or course of disease.
A database of cytokine polymorphisms and disease 23 lists over 90 case-control studies for the TNF À308 promoter SNP alone (the A allele sometimes described as Figure 1 Scheme depicting the MHC on chromosome 6p21,31, some of the genes in the TNF region and the promoter polymorphisms. Numbering is descending from the þ 1 of the transcription start site (TSS). 'Core' promoter refers to the region showing high evolutionary conservation and well-document transcription on factor binding and activity.
TNF2), and many others that analyse other TNF promoter SNPs or TNF locus microsatellites, and the literature contains many more examples. Here we discuss the relevance of TNF promoter polymorphisms to a relatively small number of conditions, selection having been to some extent arbitrary and based on the fact that a considerable number of studies have been published. Other conditions equally deserving of attention include SLE, coronary artery disease, Crohn's disease, COPD, insulin resistance, and transplant rejection.
The premise of studies of TNF promoter SNPs is that gene variants with a significant role in pathology will lead to a greater understanding of the regulatory mechanisms involved in both health and disease and may provide useful knowledge for identifying, and allowing early interventions in at-risk individuals.
The first requirement in the fulfilment of these hopes is that functional gene or gene promoter variants can be reliably and reproducibly identified, and secondly, that the regulatory mechanisms underlying pathology can be convincingly dissected.
Autoimmune disease associations
Rheumatoid arthritis TNF plays an important role in the pathogenesis of RA, which has led to great interest in genetic factors that might influence the regulation of the gene. The first study of the À308 G/A SNP in relation to RA found no association between the frequency of the SNP and the incidence of RA. 24 Two subsequent Spanish studies also found no association between either À308 or À238 SNPs and susceptibility to RA. 25, 26 A large study of Japanese RA patients (n ¼ 545) showed that while À308A was increased in RA patients, this increase was dependent on linkage to DRB1. 27 Another large Japanese study (n ¼ 387) looked at several TNF SNPs including À308, but only found that the T allele of the -857 SNP was increased in RA patients, and this link also proved to be dependent on HLA-DRB1*0405. 28 Perhaps, the most surprising finding is that while an Australian study 29 had reported an increase in the À308A allele in RA patients, two recent studies from Taiwan  30 and Sweden   31 reported an increased incidence of the À308G allele in RA patients, when compared to controls. In addition to studies of the incidence of RA, some researchers have examined the possible role of the allele variants in disease severity. One Dutch study reported no increased incidence of RA in carriers of various promoter SNPs but did find a decreased severity of erosions in À238 heterozygotes (OR 4.1, CI 1.0-17). 32 A TNF intron SNP at þ 489 has also been studied, 33 and the A allele was found to be decreased in a Dutch RA patient group (n ¼ 293), while patients that did carry the A allele, had a four-fold lower risk of developing erosive disease.
An Italian study of 163 RA patients 34 reached a similar conclusion, showing that the -238 GA/AA genotypes were reduced in patients with severe RA (OR 11.7, CI 0.6-216, P ¼ 0.03) and that the þ 489AA genotype might play a role in protection from severe disease (OR 4.2, CI 0.97-18.4, P ¼ 0.045). Other studies have used microsatellites to analyse the TNF region 26, [35] [36] [37] and found that several of these markers were associated with incidence or severity of RA, although another study 38 found that this association was not independent of the known extended haplotype associations. Recent studies have found positive associations, including for the TNF À863A, 39 and a þ 851 intronic SNP, 40 and these authors state that they are now engaged in fine mapping of a larger interval, in an attempt to identify the causative locus. Another recent study examined extended haplotypes in the MHC including only DRB1*04 patients and controls in an attempt to dissect out the additional risk loci thought to obscured by linkage to these HLA risk loci. These authors found that a single LTA-TNF haplotype was both overrepresented or underrepresented in cases dependent on the DRB1*04 type, suggesting that other loci outside the LTA-TNF region account for the increased risk. Studies of the haplotype structure of the TNF locus have described many haplotypes in this genomic region 41 and suggested that the TNF region contains a gene that makes a contribution to susceptibility independently of the contribution of HLA-DRB1. 24, 42 This gene was then identified as IkBL (NFKBIL1), 43 which has also been implicated in susceptibility to myocardial infarction. 44 Further studies are needed to show that the variants of IkBL or LTA are functional and directly contribute to the pathogenesis of RA and further fine mapping of the TNF region must rule out linkage to other disease loci.
Multiple sclerosis
Multiple sclerosis (MS) is an inflammatory condition that leads to a loss of the myelin sheaths of nerve fibers, resulting in increasing damage to the central nervous system and severe pathology. The inflammatory component and the known genetic predisposition for the disease make TNF an interesting candidate gene in this condition. The number of genetic studies on the association of TNF SNPs is already in double figures. A number of studies have found no HLA-independent association between TNF SNPs or microsatellites and MS, [45] [46] [47] [48] [49] [50] [51] childhood MS, 52 or the severity of MS. 53 While this might appear to indicate that the case for TNF SNPs and MS is closed, the highest number of patients included in any of these studies was 78. 53 Two slightly larger studies 54, 55 also found no significant associations between the À308 SNP and MS. This concurred with a larger study of the À308 and À238 SNPs involving 179 patients. 56 Several larger studies have been conducted, involving 358 57 and 283 58 patients, which also found no association between TNF SNPs and MS or the severity of MS. A recent Spanish study 59 has broken this trend by reporting that the À376 SNP is associated with susceptibility to MS, independently of the known association with HLA DRB1*1501. This report described a relatively large group of patients compared to most of the other studies, n ¼ 238, but until further studies of this SNP or a description of the haplotypes carrying À376 in the Spanish population appear, the importance of this finding remains unclear.
Ankylosing spondylitis
Ankylosing spondylitis (AS) is joint disease specifically involving the sacral (lower) region of the spine, and in its extreme forms leads to fusion and inflexibility of the vertebra of the lower spine. It is widely believed that there is an autoimmune component to the pathogenesis of AS, this idea fuelled by the strong association with the HLA allele B27 that is often cited as the classic HLA disease association. Other, probably hormonal, factors play a major role in the condition, as illustrated by strong predominance of AS in males. Several of the earliest studies on the role of TNF in AS 60, 61 found no association between promoter SNPs or other TNF markers, and a similar, more recent study, also found no association. 62 All these studies included fewer than 100 patients. In a recent study 63 examining 141 HLA B27 þ AS patients, a significant decrease was seen in the frequency of both the À308 A and À238 A alleles in the B27 þ patients in comparison with B27 þ and B27À control groups, and the authors estimated a relative risk of 0.3 for these alleles in B27 þ patients. This study was followed by a joint German/UK study 64 in which the role of these alleles in the two populations was considered. While an analysis of 96 south German AS patients also found a significantly reduced frequency of the À308 A allele, neither the À238 A allele in the German population nor either allele in a UK population was significantly associated with AS. These authors concluded that the alleles may be associated with but play no direct functional role in AS. A recent study involving 161 Spanish AS patients failed to find any association between either of these SNPs and AS. 65 This same group published a subsequent study 66 in which they reported that the À238 A allele showed a four-fold increase in a B27 negative AS patient group (n ¼ 28) compared to a B27 negative healthy control group (n ¼ 100). In a Dutch AS patient population positive for B27, neither the À376 nor the À238 SNPs were associated with AS independently of B27. 67 The contradictory results reported in these AS studies and the low numbers of patients involved make it difficult to draw any conclusion as to the relevance of these TNF promoter variants for AS pathology.
Asthma
The central role of airway inflammation in asthma and the increased levels of TNF in asthmatic lungs suggested that functional variants of the TNF gene could be important in the disease. While some studies 68, 69, 70 have found evidence for an association between À308A and asthma, one of these studies included only 20 selfreported childhood asthma cases. 70 The other studies included larger numbers of asthma cases (n ¼ 251 and 236, resp.), but both these studies reported marginal Pvalues (P ¼ 0.02 and 0.04). All three studies identified the A allele as being more frequent in asthma cases. In contrast, an Italian study of 221 asthma cases found no association of À308A with asthma, 71 and a Belgian study 72 of 95 asthmatics came to the same conclusion. Somewhat surprisingly, an Australian study including 74 asthmatic children 73 found that the G allele was significantly associated with asthma (P ¼ 0.004). Studies that have considered the extensive linkage disequilibrium (LD) present on chromosome 6 have found that extended haplotypes account for the association of TNF SNPs with asthma. 74, 75 The extended haplotype LTalphaNco*1/TNF-308*2/HLA-DRB1*02 was found to be associated with asthma (OR 6.68, P ¼ 0.002) and even more strongly associated with bronchial hyperreactivity (OR 21.9, Po0.0001) in a study of over 1000 patients. Another study also found that bronchial hyperreactivity was associated with À308A but again through an extended haplotype. 76 The genetics of TNF in asthma reflects the situation in RA in both the lack of agreement among studies as to association and the identification of both À308 alleles as risk factors. It is clearly necessary to include the typing of HLA alleles in any analysis if a meaningful conclusion is to be reached.
Infectious disease associations
It is clearly established that host-genetic factors are important in determining the outcome of infections caused by infectious pathogens. This is particularly evident in chronic infections with intracellular pathogens that can achieve a state of 'persistence' in which there is a balanced equilibrium between effective host immunity and pathogen multiplication. Examples of such diseases include mycobacterial infections (tuberculosis and leprosy), leishmaniasis, malaria, and chronic viral infections such as hepatitis B and C.
The crucial role of TNF in protective host immunity against reactivation of latent tuberculosis was recently highlighted by the observation that the relapse and severe course of tuberculosis is over-represented in RA and Crohn's disease affected patients following treatment with Infliximab. 6 There are several indications that other chronic infections may also reactivate and exacerbate following molecular inactivation of TNF.
SNPs in TNF have been found in association with several infectious diseases, including leishmaniasis, 77, 78 scarring trachoma, 79 and a fatal course of meningococcal infections, 80 although a more recent study could not confirm this association. 81 In tuberculosis no evidence was found for linkage between susceptibility to disease per se and the TNF gene cluster in affected families. 82 In one study, a TNF-associated microsatellite marker was associated with slow progression of disease in HIV infected individuals. 83 
Leprosy
Although not intensely investigated with regard to TNF gene variants, leprosy provides an interesting model disease to study the role of TNF in chronic infection and associated immunopathology. Mycobacterium leprae is a relatively poorly pathogenic bacterium, causing clinically manifest disease in only 0.1-1% of those infected. The localized or tuberculoid form of leprosy is characterized by a proinflammatory immune response, including the presence of Th1-type cytokines and TNF in granulomatous lesions. In contrast, the disseminating or multibacillary form of the disease is characterized by the absence of such features. TNF also plays an important role in the pathogenesis of acute inflammatory leprosy reactions, which are responsible for many of the sequelae that characterize leprosy. The immunosuppressant thalidomide, which inhibits TNF production, is effective in treating type-2 leprosy reactions.
A significant association between the TNF À308A allele and multibacillary leprosy has been reported from India. 84 In Brazil, however, this allele was associated with resistance against multibacillary leprosy.
85-87 A significant association of TNF À308A was found in borderline tuberculoid leprosy patients with the magnitude of in vivo delayed type hypersensitivity skin test reactivity to cutaneously injected M. leprae antigens. 88 TNF SNPs may be associated with inflammatory leprosy nerve damage, but this has not been investigated in large numbers of patients thus far. 89 More recent studies have shown that signalling deficient mutations in certain Toll like receptors (notably TLR2), which act upstream of TNF can be strongly associated with lepromatous leprosy, implicating among others, a role for TNF. 90 Malaria Strong TNF promotor SNP associations were first described in Plasmodium falciparum malaria. Clinical studies had shown correlations between high TNF levels and severe malaria. Homozygosity for the TNF À308A allele was associated with severe cerebral malaria in children in the Gambia, and with a seven-fold increased risk of death and severe cerebral malaria. 91 The same group subsequently showed an association between the TNF À238A allele and severe malarial anaemia, concluding that factors near the TNF gene influence these conditions. The ratio of antagonistic cytokines can influence the outcome of disease, as shown by Westendorp et al, 1 and the ratio in TNF/IL10 has been studied in malaria. May et al 92 found that ratios o1 were a risk factor for both cerebral malaria and severe anaemia.
A linkage study of families with mild malaria in Burkina Faso 93 found linkage to the TNF region, though not directly to promoter SNPs. A study of Gabon schoolchildren found the TNF À308A allele to be associated with shorter intervals of malaria reinfection. 94 Another Gabonese study looked at asymptomatic malaria and concluded that the TNF-238A allele confers protection against clinical malaria. 95 A study by Ubalee et al 96 of Karen and Myanmar patients with cerebral malaria found that the so-called TNFP-D allele (À238G, À308G, À857T, À863C, À1031T) was strongly elevated in both ethnic groups (Po0.001), the unique variant on this allele being the À857T SNP.
A Kenyan study looked at various aspects of malarial morbidity in young children and found the TNF À308A allele to be associated with preterm birth and death in infancy, with carriers showing a trend towards high density parasitaemia and severe malarial anaemia. 97 A Gabonese study, looking at immunological parameters in mild malaria, found that TNF À238A was associated with the level of the antibody response to the specific antigens of P. falciparum, MSA-2 and RAP-1. 98 A study from Sri Lanka found that the TNF À308A allele was associated with both severe malaria and other infections. 98 While most studies have found a positive association between the TNF À238A and -308A SNPs, some studies have failed to find any association between À308A and malaria. A study of malaria patients from Thailand found no association with disease severity on the basis of TNF À308. This finding agrees with the study of Ubalee et al, discussed above, which also failed to differentiate patients with severe symptoms on the basis of À308, but rather on the À857T carrying haplotype. A study of Tanzanian infants found several minor clinical parameters to differ in TNF À308 heterozygotes but could not find major differences in malariametric indices in heterozygotes. 99 The finding that the À857 rather than À238 or À308 SNPs associates with severe malaria in East Asian populations in contrast to the African populations described in most of the other studies may indicate population-specific linkage to the true disease locus.
Hepatitis B and C Chronic hepatitis B virus (HBV) infection can lead to a number of outcomes from asymptomatic HBV carriage to cryptic, acute or chronic hepatitis, liver cirrhosis and primary hepatocellular carcinoma. The variable clinical outcome and pattern of infection are determined by virological factors but host genetic and immunological factors also play an important role. TNF plays an important role in the pathogenesis and host immune response to infection with both the hepatitis B (HBV) and C (HCV) viruses, and may be one of the candidate genetic factors that play a role in determining the outcome of infection.
A Japanese study 100 of HBV carriers (n ¼ 213) found that both asymptomatic carriers and those progressing to chronic disease had no increased frequency of TNF SNPs. However, a Korean study of 1400 HBV infected subjects found that certain TNF haplotypes were significantly associated with HBV clearance. 101 Another study of 71 patients with chronic HBV infection found the À238A SNP to be associated with disease. 102 Various aspects of HCV disease have been studied with respect to TNF SNPs. Several studies have looked at response to therapy in HCV infected subjects, [103] [104] [105] [106] [107] [108] [109] [110] using either interferon-alpha monotherapy or a combination of IFNa and ribavirin. No study found any association between TNF SNPs and occurrence of HCV or response to therapy with these agents. Most studies that have looked at outcome of disease have found no association with TNF SNPs. 104, [111] [112] [113] [114] [115] However, two studies have appeared that did find an association of TNF SNPs with HCV. 116, 117 The latter study 117 is curious not because of the reported higher occurrence of the À238A allele among chronic HCV patients, but because the reported frequency in a healthy control group (n ¼ 99) drops from 7 117 to 3.5% in an article published concurrently by the same group. 102 Septic shock Due to the well-known role of TNF in sepsis, the prospect of identifying functional variants of this gene was very attractive. Sepsis patients may represent the tail end of the distributions for TNF production, making this population an excellent target for well-matched casecontrol studies. While an early study of the role of the À308 SNP 118 in a group of 80 patients with septic shock found no association with disease incidence, a subsequent French study 119 involving 89 patients found that the À308 A allele was both more common in patients than controls (39 vs 18%, P ¼ 0.002), and was also more frequent among those who died (54 vs 24%, P ¼ 0.008). After correction for confounders, carriage of the TNF À308 A allele was shown to lead to a 3.7-fold increase risk of death. Similarly, a US study 120 that looked at the occurrence of severe sepsis after trauma in 37 patients found that the A allele was associated with both occurrence of sepsis (OR 4.6, CI 1.9-10.9) and death (OR 2.1, CI 0.6-7.3). These findings were only partly confirmed in a Taiwanese study 121 involving 42 patients with septic shock. Here, it was found that while the A allele was not more common in patients with septic shock, carriage of the allele did result in an increased risk of death (92 vs 62%, Po0.05 ). An Australian study involving 31 patients with septic shock could not confirm these earlier findings. 122 All of these studies involved relatively small numbers of patients and even the study including 'multicentre' in its title only examined 89 patients. The question of the relation of the À308 A allele to incidence and severity of septic shock is unclear in the light of these variable findings. There is some consistency in the finding that A allele leads to an increased risk of death, although this may to be mediated through linkage to other markers such as the lymphotoxin a þ 250 SNP. 122 
Disease associations-conclusions
The studies discussed here represent only a fraction of all studies dedicated to analyzing the role of TNF SNPs and other TNF locus markers in human disease. Although a number of studies discussed can boast impressive Pvalues, there is little consistency in the findings relating to the TNF promoter SNPs. While TNF is a justifiably attractive target for many fields of genetic research due to the broad biology of TNF, the corollary is that an important functional variant of TNF might be expected to make its presence felt across a range of pathologies. This is not borne out by the results discussed above, although one might argue that TNF variants could play a role in specific diseases in conjunction with other gene variants that exhibit a more limited biology.
Several factors may explain the relatively weak association of TNF SNPs with disease or disease severity. Clearly, in any collection of studies, both false positives (type I errors) and false negatives (type II errors) may occur, and can be expected to be especially prevalent among studies including relatively small numbers of patients. Comparisons of findings between ethnic groups may not be appropriate due to population-specific masking of gene variant effects (epistasis) or geneenvironment interactions in one population. A case in point may be the study of Milicic et al. 64 Disease heterogeneity among patient groups may also lead to difficulties in the comparison of studies and their reproducibility, exacerbated by the inclusion of small groups of patients.
A further important confounder is well recognized. The selection of an appropriate control group is critical to the accurate estimation of population allele frequencies. Poorly defined control groups, possibly due to population stratification resulting from ethnic admixture within the study population, may result in poor matching with a patient group, resulting in the identification of spurious differences in allele frequencies and leading to an initial impression of an association between a gene variant and a given condition. Examples may be the study by Cvetkovic et al 31 in which the carriage of the TNF À308 G allele was found to be higher in patients compared to the control group used, while other Swedish studies, 54, 123, 124 including two previous studies from the same group 125, 126 have reported allele frequencies in healthy controls that are very similar to the patient group in this study. Similarly, Yen et al 30 included a healthy control group that showed very striking differences in allele frequencies to the patient population, but against a background of some confusion as to the true allele frequencies in the Taiwanese population. Two studies quoted lower but broadly similar allele frequencies 121, 127 while one study reported allele frequencies among healthy controls that were similar to the patient group in the Yen et al study. 128 The problem of population stratification can be overcome by use of family-based studies such as the transmission disequilibrium test, 129 which are insensitive to population heterogeneity, or by applying methods to detect population stratification. 130 Another important confounder of these studies may be linkage disequilibrium (LD). LD is the nonrandom association of alleles at adjacent genetic loci and is the result of lack of recombination between loci at meiosis, generally indicating the loci are close together, thus having a low probability of recombination or in the case of LD between distant loci, that the population within which they are found is relatively young (eg Europeans). A further complicating factor is the uneven distribution of meiotic recombination, especially in the MHC, and recent evidence indicates that patterns of LD seen in the MHC are driven chiefly by recombination hotspots rather than population history [131] [132] [133] and can vary by haplotype. 134 One of the earliest studies of the TNF promoter polymorphisms 135 showed the extent of haplotypes across the MHC. Initially, few studies attempted to fully characterize the genetic architecture of this region in the population under study, but recent studies have increasingly included more markers over a wider region and typed the HLA classes with known associations, for example, Jawaheer et al. 136 Other studies have characterized the haplotype structure of the TNF locus itself [137] [138] [139] but if the disease causing variant lies outside the TNF locus as current evidence suggests, this effort will only be the first step. The relevance, though not the function, of HLA antigens to disease is well recognized 140, 141 and may account for many of those studies that find positive evidence of association to TNF, emphasizing the role of TNF variants as markers for HLA or other disease loci located in the MHC. 136, 142 The strong evidence for the presence of other risk loci within the MHC besides the known HLA alleles may account for associations after discounting linkage to known HLA risk genes.
A major conceptual weakness of many studies is the assumption that a genuine association between a particular gene and disease will be simple, with one or a few major mutations (little locus or allele heterogeneity) accounting for the bulk of the genetic burden. This is not borne out from our experience of many monogenic diseases, [143] [144] [145] [146] in which many genetic variants may lead to an identical phenotype.
The so-called 'complex diseases', which involve many genes, may show a similar picture and imply that in some cases dozens or even hundreds of gene variants could be interacting on a population-wide basis to result in a given condition.
The fact that many diseases show a widely varying course indicates that several subgroups of patients may exist, each with a particular genetic profile. The most extreme scenario is one in which individual gene variants, of which there may be many (eg CFTR41000), 147 can combine with numerous variants of several other 'disease' genes to create a unique genetic profile for each patient.
Although there is little evidence for such a grim scenario in the case of complex diseases, the true situation remains unclear.
The weaknesses of many case-control studies has been discussed extensively in recent literature [148] [149] [150] [151] and highlighted the fact that several initially interesting findings from relatively large studies have been undermined by still larger studies that failed to replicate the original finding. 152 In a recent comprehensive review of over 600 positive case-control studies, only six positive associations were found to have been consistently replicated. 153 A follow-up meta-analysis of a selection of the positive associations by the same authors found that eight of 25 associations were statistically significant. However, the odds ratios revealed modest genetic effects, varying from 1.07 to 2.28, emphasizing the need for large study populations. 154 The plethora of irreproducible studies has led the editors of Nature Genetics to insist on basic requirements for case-control studies including large sample sizes, small P-values, associations that make biological sense, and detail alleles that have a relevant physiological function. In addition, an initial study should be accompanied by an independent replication, the association should be reproduced in both population and family studies, and detail high attributable risk/ odds ratios. 155 This sets the bar very high and few of the TNF studies discussed here could clear it. Meeting these criteria will mean that fewer, more rigorous, studies will be reported but that the identification of genuine associations to genetic loci will increase.
There has long been good evidence for risk loci in other regions of the MHC than those encoding the HLA genes, and recent reports may be bringing us close to the real risk loci. 43, 44, 136, 156 From the studies discussed above it is clear that certain diseases are not associated in any way with the TNF region, including MS and the response to interferon-alpha therapy of hepatitis, but the inconsistency of the reports with regard to other diseases perhaps suggests that in these cases a genuine linkage may exist to a nearby disease-causing locus. In the light of the factors discussed above, this impression may simply result from a small number of poorly conducted studies, or from ethnic factors determining linkage, but confirmation requires large studies that include a broad region of the MHC.
Functional studies of the TNF Promoter
Just as the central role of TNF in the inflammatory response has provided the main justification for many case-control studies, it has also inspired many biochemical studies of the function of the promoter. Several reviews have covered various aspects of TNF transcriptional regulation. 17, 18 It is important to note that the first 200 bp of the promoter are highly conserved across a range of species, with the murine, bovine and porcine promoters showing approximately 80% homology with the human promoter, while further upstream there is far less conservation between species. 18 No SNPs have been identified in this proximal portion of the promoter, where they might be expected to be able to influence transcription, while those that have been reported, all occur in regions that have no clearly established functional significance. Most of the factors that have been convincingly described as being involved in TNF transcription, including CREB, 157 C/EBPa þ b, [158] [159] [160] NFATp, [161] [162] [163] 172, 173 these regions harbour no known SNP. These considerations place a heavy burden of proof on data claiming to show functional activity outside of the 'core' promoter, or other regions for which there is independent evidence of protein binding.
Studies that have examined the direct functional role of SNPs in the production of TNF have used three approaches. Several studies have looked directly at the production of TNF in whole blood stimulations and this approach has been extended to include numbers of TNF positive cells, although this provides less compelling evidence for the actual increase in total TNF. A second, widely applied approach, has been to use various in vitro methods including the electrophoretic mobility-shift assay (EMSA), but particularly the transient transfection technique in which artificial promoter constructs differing in the SNPs under investigation, are introduced into various cell lines. The resulting difference in the activity of the linked reporter gene (eg CAT or luciferase) then allows any differences in promoter activity to be measured. A third technique, which has been less widely applied, is the quantification of the RNA transcripts. Due to the presence of a common SNP in the first intron of the TNF gene pre-mRNA transcripts from the respective alleles can be distinguished. Individuals carrying both one copy of this SNP and SNPs in the promoter should produce different levels of transcripts from individual alleles if these promoter SNPs are functional, and the activity of both alleles can then be distinguished and quantified.
Ex vivo TNF production
Early reports on the correlation between SNPs and TNF production by LPS stimulated monocytes found no significant differences. 174-176. A study involving a small number of heart transplant recipients (n ¼ 22) also found no differences in a whole blood stimulation assay. 177 Two small studies (no53) also failed to find a correlation between SNPs and TNF production. 178, 179 Several larger studies have been conducted. A study by Huizinga et al 56 involving 179 subjects used a whole blood LPS stimulation assay, but found no statistical difference dependent on the 308 genotype. Kubota et al 180 analysed circulating levels of TNF in patients with congestive heart failure (n ¼ 211), but could not detect any correlation with TNF genotype. Recently, a study of 129 healthy individuals also failed to detect a difference in TNF production-dependent on genotype. 181 A number of relatively small studies have received much attention. Bouma et al 182 measured the production of TNF by the T-cell compartment of PBMCs from 42 subjects with a mixed disease/healthy profile and found an increase in TNF levels dependent on TNF genotype with the carriers of the À308 A allele showing higher levels (P ¼ 0.03). Louis et al 8 measured the production of TNF (62 healthy subjects) in a whole-blood stimulation assay using LPS. These authors reported that the production of TNF was significantly higher among carriers of the À308 A allele vs noncarriers, even after correction for numbers of CD14 þ cells (Po0.01). Similarly, Tang et al 121 measured the levels of TNF in a whole-blood assay of patients experiencing septic shock and found that the carriers of the -308 A allele had significantly higher levels (Po0.05). The Con-A stimulation of PBMCs derived from liver recipients (n ¼ 53) showed a significant difference dependent of TNF genotype with -308AA showing three times the level seen in GG (P ¼ 0.006).
183
It is unclear why these studies contradict each other. One confounder may be the low numbers of patients examined in many studies. Moreover, the inclusion of mixed groups of subjects may introduce greater variation. TNF is known to vary widely between individuals, making any measurement in a small group a difficult enterprise. These studies also differed in time periods after stimulation, concentrations of stimuli used, and the absolute values of TNF in pg/ml reported.
In a recent study on the influence of TNF SNPs on experimental human endotoxemia, 184 12 volunteers typed for À308 (6 ¼ GG, 5 ¼ GA, 1 ¼ AA) showed no significant difference in peak TNF plasma levels after challenge with LPS.
In vitro studies of promoter SNP activity A number of groups have published functional studies of promoter variants, with many concentrating on the À308 SNP. The methodology of these studies has been broadly similar, with a variety of in vitro techniques applied to address the question of whether proteins bind to DNA probes containing allelic variants of the site under investigation (EMSA); and whether DNA constructs, consisting of reporter genes whose expression is regulated by allelic variants of promoters, show differences in transcriptional activity (transient transfection of reporter constructs). An early study by Brinkman et al 185 found no differences in the activity of two allelic variants of the À308 SNP, either with or without the presence of the 3 0 UTR. Another, very similar, study came to the same conclusions. 186 In contrast, a study by Wilson et al 187 has received considerable attention since its publication and showed large differences in transcriptional activity between allelic constructs, with the -308A construct having over eight-fold higher basal activity in Raji B cells. Unlike several other similar studies that analysed constructs differing at À308, 46, 188 , which suffered from obvious technical weaknesses, the only clear anomaly of the Wilson study was the resistance of the TNF construct to induction by PMA. We have used various TNF À308G promoter constructs in transfection of the Raji B cell line and never found these to be resistant to induction. [189] [190] [191] Wilson et al were also unable to provide evidence of a major difference in affinity of DNA binding proteins in this study. Another group has published several studies 192, 193 using À308 constructs and were unable to detect a difference in the activity of variants lacking the 3 0 UTR in contrast to Wilson et al, but did observe differences when the 3 0 UTR was present, in contrast to the study of Brinkman et al.
All these studies included promoter constructs that carried polymorphisms reflecting those found in nature, À238, À308 and À376. Studies in our laboratory showed that introduction of these constructs into cell lines produced no evidence that these polymorphisms had any influence on the activity of the promoter. 185, 190 However, it remained possible that the relatively minor changes present in these promoter variants produce an effect that is too subtle to detect. We therefore decided to remove larger regions, consisting of 10 bp regions around the promoter polymorphisms, and replace them with an irrelevant sequence, reasoning that replacing a relatively large region of the promoter around a possible regulatory site would prevent any activator/inhibitor protein binding and therefore result in a measurable functional effect. 191 These studies produced no evidence for the functionality of constructs that replaced the À308 and À376 regions; however, we did see a small increase in basal transcription of constructs covering the À238 region. Previous studies of this region have suggested that it contains a strong repressor site. 194, 195 Quantification of allele specific RNA transcripts (ASTQ) In addition to the investigative methods described above, another technique can be applied to establish whether alleles are subject to differential regulation. This is to quantify the RNA transcripts produced by each allele individually in primary cells. Digestion of RT-PCR products derived from stimulated PBMCs of individuals who are heterozygotes for an intragenic polymorphism that allows allelic TNF transcripts to be distinguished, which are then be quantified by radioactive labelling and gel electrophoresis of the digestion products. We applied this method, known as allele-specific transcript quantification (ASTQ), to determine the direct transcriptional activity of each allele. While we initially used the rare þ 70 SNP, 196 which allows the ratios of mRNA transcripts to be estimated, we later switched to the use of the common intron SNP at þ 489, 197 because this can be found in conjunction with various promoter SNPs, allowing the study of possible differential transcription mediated by these SNPs. As prespliced mRNA is measured, this estimation is independent of the possible influence of a higher turnover of a given allele. In both these studies, we found that each TNF allele contributes essentially equally to the mRNA or pre-mRNA pools in both PBMCs of heterozygous healthy individuals and synovial tissue of RA patients. The inclusion of individuals heterozygous for TNF-308, TNF-863, TNF-857, and TNF-1031 in this study revealed no differences in transcriptional activity dependent on these SNPs.
HaploChIP
An innovative new approach to the estimation of allelespecific transcription has recently been described, termed haploChIP, 198 which involves the crosslinking of RNA polymerase II (Pol II) and DNA, immunoprecipitation of phosphorylated Pol II, and amplification of coprecipitated DNA. DNA loading is a surrogate for transcriptional activity, and these authors showed a correspondance between DNA loading and mRNA levels of the lymphotoxin a gene (LTA). This method does not require a transcribed marker in the mRNA, and seems to show a reasonable correspondance with mRNA levels. Whether this method is an improvement on the ASTQ technique is not immediately clear. The estimation of the relative levels of mRNA is simple, accurate, and direct, given the presence of transcribed marker. In the absence of a marker in the mRNA transcript, precursor RNA levels can be estimated, as described above for the TNF gene, but this is less accurate and more technically demanding, although the signal-to-noise ratio seems to compare favourably with that of the LTA gene analysed by Knight et al. 198 In the context of TNF, Knight et al confirmed the findings from the ASTQ analysis, demonstrating that the TNF-308 SNP does not mediate differential expression in EBV-transformed B cell lines.
TNF promoter methylation
The attempts to dissect the functionality of the TNF promoter have all concentrated on the genetic aspects of TNF gene regulation, but now with the increasing interest in the epigenetic control of gene regulation and possible significance for disease, it is surprising that little attention has been paid to the possibility that aberrant methylation could play a role in TNF disregulation. A number of reports have shown that the TNF promoter can be methylated and that this may affect promoter function. [199] [200] [201] [202] The nucleotides at À238 and À244 form part of the last two methylated CpGs before the generally unmethylated core promoter, and genetic ablation of these sites might affect the methylation boundaries of the promoter. This is perhaps the most underexplored aspect of TNF gene regulation.
Discussion
Study of the role of TNF promoter SNPs in human disease has been an important and legitimate avenue of investigation, both in case-control studies and studies that have investigated the possible functionality of these SNPs. This review has not been exhaustive and present or future studies may, after repeated confirmation, conclusively show an association with a particular disease, or convincingly describe a functional aspect of TNF SNPs. However, the studies discussed here suggest that this is an overly optimistic view. There is no casecontrol study or functional study for which there is not at least one, or more often, many other studies that reach an opposite conclusion. The absence of consensus in this field does not mean that these SNPs have no biological function or that all positive associations are spurious, but it does show the underlying biology, if it exists, will not reveal itself easily.
There is no way of determining, a priori, what the contribution of a functional gene variant to a population disease profile will be. However after many investigations, as is the case for TNF genetics, it will become clear whether this effect is major or minor. It is clear that if there is a role for any TNF gene variant in the pathogenesis of any of the conditions discussed above, it will be either minor or specific. The approach and rigour of many of the studies discussed above is inadequate to effectively confront this reality. Equally, the technology employed to investigate the functional aspects of these SNPs has apparently proved inadequate to produce consistent results across different laboratories.
Many of the studies described were based on the hypothesis that genetic variants of the TNF locus must be involved in diseases where TNF is clearly involved in pathogenesis. Assured by claims that the À308 polymorphism is functional, these studies confined themselves to typing TNF SNPs and, in general, have produced mixed results. Studies based on the strong genetic data suggesting other risk factors besides known MHC associations but considering the wider MHC have recently been successful in identifying candidate functional SNPs. There is strong evidence for two further genetic loci in RA, besides the well established risk attributable to HLA DRB1, but these loci extend over a large region including many genes. 136 The recent identification of the IkBL (NFKBIL1) gene as the second MHC susceptibility locus for RA with the identification of a IkBL promoter SNP (À62) as disrupting a putative binding motif for a transcription repressor 43 demonstrates that broad mapping of the MHC is a powerful strategy. Interestingly, this locus was also identified in studies of myocardial infarction 44 and breast cancer susceptibility. 156 Okazi et al 44 opted for LTA as their disease causing locus, and showed that two variants were functional in in vitro assays, which is supported by the recent identification of differential expression from LTA alleles. 198 However, they also showed that the IkBL promoter SNP (described as À63) affects promoter activity in transient transfection assays, illustrating the difficulty of clearly identifying the causative genetic lesion. Further study will reveal if these or other nearby variants are the true disease-modifying loci.
If there is to be any true advance in this field, then future case-control studies will have to be carefully conducted and have sufficient power to detect associations much weaker than those currently postulated. The laboratory techniques used to identify functional SNPs also need improvement, and new techniques need to be developed and existing advances, such as ASTQ and haploChIP, to be more widely adopted.
If a candidate gene approach is to be used, with the ever-growing number of SNPs that are being catalogued, an informed selection of SNPs has become possible. SNPs should have the potential to change biological function, such as nonsynonymous changes in important regions of a protein, or should be in proven regulatory regions of a gene, with convincing biochemical evidence of function. Finally, an adequate knowledge of the biology of the protein in question should make its role in disease plausible. The TNF SNPs only partly meet these criteria, and as the biology of inflammation is further unravelled other genes and gene variants will become equally plausible candidates, of which there are already many examples.
Equally it is clear that unless the functionality of a gene variant is proven beyond doubt, the analysis of haplotypes in candidate regions and genome-wide analysis if candidate regions have not yet been identified, will be the more productive approach. While these approaches are both technically and financially more demanding, past case-control studies show that their adoption is inevitable. Recent studies have shown the way forward, but also highlighted the difficulty of demonstrating the functionality of a variant when it is found.
